Yin JY, Yang TY, Yang BQ, Hou CX, Li JN, Li Y, Wang Q. FibroScan-aspartate transaminase: A superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis. World J Gastroenterol 2024; 30(18): 2440-2453 [PMID: 38764767 DOI: 10.3748/wjg.v30.i18.2440]
Corresponding Author of This Article
Qi Wang, MD, PhD, Associate Professor, Associate Research Scientist, Chief Physician, Doctor, Teacher, Center of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshun East Street, Chaoyang District, Beijing 100015, China. wangqidl04@ccmu.edu.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Jing-Ya Yin, Tian-Yuan Yang, Bing-Qing Yang, Qi Wang, Center of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
Chen-Xue Hou, Yue Li, Department of Pathology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
Jun-Nan Li, Beijing institute of infectious disease, Beijing 100015, China
Yue Li, Qi Wang, Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
Author contributions: Yin JY and Yang TY contributed equally to this work; Wang Q and Li Y provided idea for this research and were co-corresponding authors; Yin JY, Yang TY, Yang BQ, Hou CX and Li Y critically revised the manuscript; Yin JY, Yang TY and Wang Q wrote the manuscript and performed the statistical analyses; Li JN performed a rigorous biostatistical review of the statistical methods presented in the manuscript; All authors read and approved the final manuscript.
Supported byNational Natural Science Foundation of China, No. 82170591; and Natural Science Foundation of Beijing, No. 7222097.
Institutional review board statement: The study was reviewed and approved by the Beijing Ditan Hospital, Capital Medical University Institutional Review Board.
Informed consent statement: This is a retrospective study, and informed consent is waived.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: All data collected during the study are available from the corresponding author at wangqidl04@ccmu.edu.cn.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qi Wang, MD, PhD, Associate Professor, Associate Research Scientist, Chief Physician, Doctor, Teacher, Center of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshun East Street, Chaoyang District, Beijing 100015, China. wangqidl04@ccmu.edu.cn
Received: January 15, 2024 Revised: March 19, 2024 Accepted: April 25, 2024 Published online: May 14, 2024 Processing time: 116 Days and 22.3 Hours
Core Tip
Core Tip: Patients with high-risk metabolic dysfunction-associated steatohepatitis (MASH) are more likely to develop cirrhosis or hepatocellular carcinoma. Early diagnosis, particularly without a liver biopsy, presents significant challenges. Exploring non-invasive models may increase detection efficiency. Although metabolic dysfunction-associated steatotic liver disease originates from non-alcoholic fatty liver disease, patient cohorts do not entirely overlap. Our study validated the concordance between these two distinct populations. To determine the effective replacement of liver biopsy with non-invasive models for diagnosing high-risk MASH, we utilized existing data to select seven diagnostic methods and assessed their diagnostic value for high-risk MASH.
